Data collection and analysis
Two review authors independently screened the titles and abstracts of 287 records, along with the full text of seven reports. Two studies met review inclusion criteria. Two review authors independently extracted outcome data and assessed risk of bias. We extracted data from only one study and conducted GRADE assessments for the following outcomes: successful treatment of exacerbation; response rates; and serious adverse events.
Main results
Two randomised trials assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy in a total of 118 adults with a mean age of 62.8 years. One multi-centre trial compared inhaled tobramycin plus oral ciprofloxacin versus ciprofloxacin alone, and one single-centre trial compared nebulised gentamicin plus systemic antibiotics versus a systemic antibiotic alone. Published papers did not report study funding sources.
Effect estimates from one small study with 53 adults showed no evidence of treatment benefit with oral plus inhaled dual therapy for the following primary outcomes at the end of the study: successful management of exacerbation -cure at day 42 (odds ratio (OR) 0.66, 95% confidence interval (CI) 0.22 to 2.01; 53 participants; one study; very low-quality evidence); number of participants with Pseudomonas aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24; 53 participants; one study; very low-quality evidence); and serious adverse events (OR 0.48, 95% CI 0.08 to 2.87; 53 participants; one study; very low-quality evidence). Similarly, researchers provided no evidence of treatment benefit for the following secondary outcomes: clinical response rates -relapse at day 42 (OR 0.57, 95% CI 0.12 to 2.69; 53 participants; one study; very low-quality evidence); microbiological response rate at day 21 -eradicated (OR 2.40, 95% CI 0.67 to 8.65; 53 participants; one study; very low-quality evidence); and adverse events -incidence of wheeze (OR 5.75, 95% CI 1.55 to 21.33). Data show no evidence of benefit in terms of sputum volume, lung function, or antibiotic resistance. Outcomes from a second small study with 65 adults, available only as an abstract, were not included in the quantitative data synthesis. The included studies did not report our other primary outcomes: duration; frequency; and time to next exacerbation; nor our secondary outcomes: systemic markers of infection; exercise capacity; and quality of life. We did not identify any trials that included children.
Authors' conclusions
A small number of studies in adults have generated high-quality evidence that is insufficient to inform robust conclusions, and studies in children have provided no evidence. We identified only one dual-therapy combination of oral and inhaled antibiotics. Results from this single trial of 53 adults that we were able to include in the quantitative synthesis showed no evidence of treatment benefit with oral plus inhaled dual therapy in terms of successful treatment of exacerbations, serious adverse events, sputum volume, lung function, and antibiotic resistance. Further high-quality research is required to determine the efficacy and safety of other combinations of dual antibiotics for both adults and children with bronchiectasis, particularly in terms of antibiotic resistance.
P L A I N L A N G U A G E S U M M A R Y

Dual antibiotics for bronchiectasis
Background to the question
Bronchiectasis is a lung disease involving abnormal airways, leading to repeated chest infections, and associated with a mortality rate more than twice that of the general population. Although previously considered a relatively rare disease, numbers appear to be increasing, particularly for those over 75 years in low/middle-income countries. Antibiotics are the main therapy for chest infection, but their use must be weighed against potential side effects and the risk of increasing resistance to antibiotic therapy. One strategy to improve response and/or reduce antibiotic resistance involves giving two antibiotic agents at the same time: dual antibiotic therapy. This review therefore aimed to evaluate the effects of dual antibiotics for treatment of adults and children with bronchiectasis.
Study characteristics
In October 2017, we identified two relevant studies comparing oral plus inhaled dual therapy versus oral therapy alone. They included a total of 118 adults with an average age of 62.8 years. One study compared inhaled tobramycin plus oral ciprofloxacin with oral ciprofloxacin, and the second study compared inhaled gentamicin plus a systemic (affecting the whole body, rather than just the lungs) antibiotic with a systemic antibiotic alone. Only a research summary was available for the latter. Published papers did not report study funding sources
Main results
S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Oral + inhaled dual therapy compared with oral monotherapy for bronchiectasis Patient 
GRADE Working Group grades of evidence High quality:
We are very conf ident that the true ef f ect lies close to that of the estim ate of the ef f ect M oderate quality: We are m oderately conf ident in the ef f ect estim ate: The true ef f ect is likely to be close to the estim ate of the ef f ect, but there is a possibility that it is substantially dif f erent Low quality: Our conf idence in the ef f ect estim ate is lim ited: The true ef f ect m ay be substantially dif f erent f rom the estim ate of the ef f ect Very low quality: We have very little conf idence in the ef f ect estim ate: The true ef f ect is likely to be substantially dif f erent f rom the estim ate of ef f ect a Downgraded one point f or high risk of bias f rom incom plete outcom e data b Downgraded 2 points owing to im precision (wide conf idence intervals crossing the line of no ef f ect and f ew events)
B A C K G R O U N D Description of the condition
Bronchiectasis not attributable to cystic fibrosis has been described as non-CF bronchiectasis but, in accordance with current clinical guidelines, we will referred to it as "bronchiectasis" throughout this review (Polverino 2017). Bronchiectasis is a persistent respiratory condition associated with progressive destruction of the airways due to a 'vicious cycle' of recurrent bacterial infection, pulmonary inflammation, and consequent structural damage (Cole 1997; Pasteur 2010). The pathological process of bronchiectasis leads to disruption of the normal epithelial barrier, which consequently allows inhaled pathogens to both colonise the airways and cause clinical episodes of infection (Cole 1986 
Description of the intervention
How the intervention might work
Chronic bacterial airway colonisation commonly occurs in patients with bronchiectasis; high bacterial load is associated with increased inflammation and symptoms and worse quality of life 
Why it is important to do this review
The benefits and risks of dual antibiotics given for management of acute exacerbations and for prophylaxis are currently unclear. 
O B J E C T I V E S
To evaluate the effects of dual antibiotics in the treatment of adults and children with bronchiectasis.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included randomised controlled trials (RCTs) reported as full text, those published as abstract only, and unpublished data.
Types of participants
We included adults and children with a clinical diagnosis of bronchiectasis confirmed by plain film chest radiography or HRCT. We excluded studies in which participants had received continuous or high-dose antibiotics immediately before the study began or a diagnosis of cystic fibrosis (CF), sarcoidosis, or active allergic bronchopulmonary aspergillosis.
Types of interventions
We included studies comparing dual antibiotics versus a single antibiotic, provided that both arms included a common route of administration. We planned to analyse short-course (< 4 weeks) and long-term (≥ 4 weeks) dual antibiotics separately. This review focused on comparisons of antimicrobial agents and therefore excluded comparisons of macrolides owing to their anti-inflammatory properties. Potential comparison groups for dual therapy versus monotherapy included the following. 1. Oral dual therapy versus oral monotherapy. 2. Intravenous dual therapy versus intravenous monotherapy. 3. Oral + inhaled dual therapy versus oral monotherapy. 4. Oral + intravenous dual therapy versus oral monotherapy. 5. Inhaled + intravenous dual therapy versus inhaled monotherapy.
6. Inhaled + oral dual therapy versus inhaled monotherapy. 7. Intravenous + inhaled dual therapy versus intravenous monotherapy.
8. Intravenous + oral dual therapy versus inhaled monotherapy. We included studies that compared one combination of antibiotics versus another if a comparison was made between different classes of antibiotics in combination (e.g. cephalosporin A + aminoglycoside A vs cephalosporin B + inhaled aminoglycoside B) or between different administration routes for antibiotics from the same class (e.g. IV cephalosporin + IV aminoglycoside vs IV cephalosporin + inhaled aminoglycoside).
Types of outcome measures
Primary outcomes
1. Successful treatment of exacerbation 2. Length of exacerbation 3. Length of hospitalisation 4. Time to next exacerbation 5. Frequency of exacerbations 6. Serious adverse event -We used the definitions from Hansen 2015 to describe serious adverse events, which were those that resulted in death or life-threatening events; requirement for hospitalisation or prolongation of existing hospitalisation; persistent or significant disability; or congenital anomalies, or events that were considered medically important.
Secondary outcomes
1. Response rates as defined by study authors (e.g. diary cards of physician global assessment) 2. Sputum volume and purulence 3. Measures of lung function (e.g. forced expiratory volume in one second (FEV 1 )) 4. Systemic markers of infection (e.g. leucocyte count, Creactive protein (CRP), erythrocyte sedimentation rate (ESR)) 5. Adverse events (e.g. cardiac arrhythmias, GI symptoms, hearing impairment, nephrotoxicity) 6. Deaths 7. Emergence of resistance to antibiotics 8. Exercise capacity (e.g. Six-Minute Walk Distance (6MWD)) 9. Quality of life (e.g. St George's Respiratory Questionnaire (SGRQ)) 10. Adverse/side effects Reporting one or more of these outcomes was not a study inclusion criterion for this review.
Search methods for identification of studies Electronic searches
We identified studies from the Cochrane Airways Trials Register, which is maintained by the Information Specialist for the Group. The Cochrane Airways Trials Register contains studies identified from several sources.
1. 7. Handsearches of the proceedings of major respiratory conferences. Studies contained in the Trials Register are identified through search strategies based on the scope of Cochrane Airways. Details of these strategies, as well as a list of handsearched conference proceedings, are provided in Appendix 1. See Appendix 2 for search terms used to identify studies for inclusion in this review. We will search the following trials registries.
1. US National Institutes of Health Ongoing Trials Register ClinicalTrials.gov (www.clinicaltrials.gov).
2. World Health Organization International Clinical Trials Registry Platform (apps.who.int/trialsearch). We searched the Cochrane Airways Trials Register and additional sources from inception to October 2017, with no restriction on language of publication.
Searching other resources
We checked the reference lists of all primary studies and review articles for additional references. We also searched for errata or retractions from included studies published in full text on PubMed (www.ncbi.nlm.nih.gov/pubmed) and reported the search date.
Data collection and analysis
Selection of studies
Two review authors (LF and SG) independently screened titles and abstracts of all studies identified for inclusion as a result of the search and coded them as 'retrieve' (eligible or potentially eligible/ unclear) or 'do not retrieve.' The same two review authors independently screened retrieved full-text study reports or publications for inclusion and recorded reasons for exclusion of ineligible studies.
They reported no disagreements with regard to study selection. We recorded the study selection process using a PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) flow diagram and study details using Characteristics of excluded studies tables (Moher 2009).
Data extraction and management
We used a data collection form, piloted on at least one study in the review, to record study characteristics and outcome data. One review author (RA) extracted the following study characteristics from included studies.
1. Methods: study design, total duration of study, details of any 'run-in' period, number of study centres and locations, study setting, withdrawals, dates of study.
2. Participants: N, mean age, age range, gender, severity of condition, diagnostic criteria, baseline lung function, smoking history, inclusion criteria, exclusion criteria.
3. Interventions: intervention, comparison, concomitant medications, excluded medications.
4. Outcomes: primary and secondary outcomes specified and collected, time points reported. 5. Notes: funding for trial, notable conflicts of interest of trial authors. Two review authors (DL and LF) independently extracted outcome data from included studies and noted in the Characteristics of included studies table when outcome data were not reported in a useable way. We resolved disagreements by consensus or by consultation with a third review author (SS or SJM). One review author (DL) transferred data into Review Manager (RevMan 2014). We double-checked that data had been entered correctly by comparing data presented in the systematic review with those provided in the study reports. A second review author (RA) spot-checked study characteristics for accuracy against the trial report.
Assessment of risk of bias in included studies
Two review authors (DL and LF) independently assessed the risk of bias for each study using the criteria outlined in the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011). We resolved disagreements by discussion with another review author (SS). We assessed risk of bias according to the following domains.
1. Random sequence generation. 2. Allocation concealment. 3. Blinding of participants and personnel. 4. Blinding of outcome assessment. 5. Incomplete outcome data. 6. Selective outcome reporting. 7. Other bias. We graded each potential source of bias as high, low, or unclear and provided a quote from the study report together with a justification for our judgement in the 'Risk of bias' table. We summarised risk of bias judgements across different studies for each of the domains listed. We considered blinding separately for different key outcomes when necessary (e.g. for unblinded outcome assessment, risk of bias for all-cause mortality may be very different from risk of bias for a patient-reported pain scale). When information on risk of bias was related to unpublished data or correspondence with a trialist, we noted this in the 'Risk of bias' table. When considering treatment effects, we took into account risk of bias for studies that contributed to those outcomes.
Assessment of bias in conducting the systematic review
We conducted the review according to the published protocol (Felix 2017).
Measures of treatment effect
We analysed dichotomous data as odds ratios, and continuous data as mean differences or standardised mean differences. We entered data presented as a scale with a consistent direction of effect. We intended to undertake meta-analyses only when this was meaningful (i.e. when treatments, participants, and the underlying clinical question were similar enough for pooling to make sense). However, data were available from only one included study, and meta-analysis was not possible. Nevertheless, we included the data narratively in the review. We planned to narratively describe skewed data reported as medians and interquartile ranges. If multiple arms had been reported in a single trial, we planned to include only the relevant arms. Similarly, if two comparisons (e.g. drug A vs placebo and drug B vs placebo) had been combined in the same meta-analysis, we would have halved the control group to avoid double-counting. None of the included studies included more than two study arms.
Unit of analysis issues
In all included studies, the unit of analysis was the participant. In terms of exacerbation rates and hospitalisation rates, we focused on the number of events experienced by the participant during the trial and analysed the results using rate ratios when possible.
Dealing with missing data
We contacted investigators or study sponsors to verify key study characteristics and to obtain missing numerical outcome data (e.g. when a study was identified as abstract only). When this was not possible, and the missing data were considered a serious source of bias, we had planned to perform a sensitivity analysis to explore the impact of including such studies in the overall assessment of results. One of the included studies was an abstract for which contact details for the principal investigator were not reported. We contacted the institution to which the authors were affiliated to obtain more information.
Assessment of heterogeneity
We planned to use the I² statistic to measure heterogeneity among studies in meta-analyses; in the presence of substantial heterogeneity, we would have explored possible causes by performing prespecified subgroup analyses. As we conducted no meta-analyses, we did not assess heterogeneity.
Assessment of reporting biases
Only two studies met the inclusion criteria; thus we identified fewer than the recommended minimum number of eight studies required to create a funnel plot to explore possible small-study and publication biases. We were not able to pool the included studies and therefore were unable to explore small-study and publication biases.
Data synthesis
We planned to use a random-effects model for meta-analyses and to perform a sensitivity analysis using a fixed-effect model, but this was not possible, as we were unable to pool data from the included studies.
'Summary of findings' table
We created a 'Summary of findings' table using the following primary and secondary outcomes: exacerbations, hospitalisations, serious adverse events, response rates, deaths, and quality of life. We used the five GRADE considerations (study limitations, consistency of effect, imprecision, indirectness, and publication bias) to assess the quality of evidence related to included studies that contributed data on our prespecified outcomes. We followed methods and recommendations described in Section 8.5 and Chapter 12 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011), and we used GRADEpro software (GRADEpro GDT). We justified all decisions to downgrade or upgrade the quality of studies by using footnotes and inserted comments to aid the reader's understanding of grades when necessary.
Subgroup analysis and investigation of heterogeneity
We planned to carry out the following subgroup analyses.
1. Duration: short (< 4 weeks) or longer (≥ 4 weeks). 2. Type of antibiotic: aminoglycosides, beta-lactams, chloramphenicol, fluoroquinolones, macrolides, tetracyclines.
3. Children versus adults. 4. Pseudomonas colonisation versus no Pseudomonas colonisation. We planned to use the following outcomes.
1. Exacerbations. 2. Hospitalisations. 3. Serious adverse events. We planned to use the formal test for subgroup interactions provided in Review Manager (RevMan 2014). However data available from the two included studies were insufficient to permit subgroup analyses.
Sensitivity analysis
We planned to evaluate the impact of methodological quality of included studies using the following domains to remove studies at high or unclear risk of bias: random sequence generation and allocation concealment. Data were insufficient to undertake sensitivity analyses. 
R E S U L T S Description of studies
Participants
The two studies included a total of 118 participants (Bilton 2006 = 53; Hossain 2010 = 65). Adults (72% female) aged 18 to 80 years with a mean age of 62.8 years (± 11.5 years) participated in Bilton 2006. Bronchiectasis was confirmed by HRCT scan, and researchers excluded from the study those with CF, allergic bronchopulmonary aspergillosis, active tuberculosis, glucose-6-phosphate dehydrogenase deficiency, significant renal disease, or change in steroid therapy within 2 weeks of the acute exacerbation. In addition, eligibility criteria included a history of chronic P aeruginosa, confirmed by sputum culture, during the previous 12 months and at screening. Furthermore, the P aeruginosa isolate had to demonstrate sensitivity to ciprofloxacin (minimum inhibitory concentration ≤ 4 µg/mL) at study enrolment. The second study was reported as an abstract alone and did not provide detailed information on participant characteristics or study inclusion/exclusion criteria (Hossain 2010).
Smoking history
In Bilton 2006, one participant was a current smoker (placebo/ oral ciprofloxacin group) and 20 participants (13 placebo/oral ciprofloxacin; 7 tobramycin/oral ciprofloxacin) were former smokers. Hossain 2010 did not report smoking history.
Interventions
Both studies assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy. 
Outcomes
Primary outcomes
Successful treatment of exacerbation
Length of hospitalisation
Only Hossain 2010 reported this outcome.
Serious adverse events
Only Bilton 2006 reported this outcome. This study reported the proportions of participants who required hospitalisation and treatment for worsening symptoms such as dyspnoea, cough, chest pain, or tightness that was associated with bronchiectasis and chronic infection.
Length of exacerbation, time to next exacerbation, frequency of exacerbations
The included studies did not report any of the above remaining primary outcomes.
Secondary outcomes
Response rates as defined by study authors (e.g. diary cards of physician global assessment)
Bilton
Researchers classified sputum culture as "eradicated" (no P aeruginosa infection and/or inability to produce sputum), "persistent" (with P aeruginosa infection and/or treatment with additional antibiotics for continued infection), "superinfected" (new pathogen and new or worsening symptoms of infection), or "indeterminate" (unable to classify).
Sputum volume and purulence
Only Bilton 2006 reported sputum volume. Neither of the included studies reported sputum purulence. 
Deaths
Bilton 2006 and Hossain 2010 did not report this outcome measure, and it remains unclear whether any deaths occurred during the study period. In Bilton 2006, 7 of 10 withdrawals were due to adverse events, but study authors did not provide follow-up data, so we do not know whether any deaths occurred in this group.
Emergence of resistance to antibiotics
Bilton 2006 reported emergence of P aeruginosa resistance to ciprofloxacin and tobramycin.
Adverse/side effects
Bilton 2006 reported adverse effects of study medications.
Systemic markers of infection, exercise capacity, quality of life
Included studies did not report any of the above outcomes.
Notes
Neither of the included studies reported information on power calculation to inform sample size, trial registration, funders, or the role of sponsors. Trial authors did not provide conflict of interest statements. Bilton 2006 reported that researchers obtained ethical approval for their trial.
Excluded studies
We recorded reasons for exclusion of five studies following examination of full text reports (see Characteristics of excluded studies). Two studies did not meet study inclusion criteria for the intervention, as the comparison arm was not given monotherapy (Orriols 1999; Orriols 2015). We excluded the remaining three studies because participants were not exclusively patients with bronchiectasis and we were unable to contact trial authors to obtain information on these participants alone (Takamoto 1994; Vergnon 1985; Watanabe 1990).
Risk of bias in included studies
Two independent review authors (DL and LF) agreed on judgements reported under the 'Risk of bias' section at the end of each Characteristics of included studies table. 
Allocation
We judged Bilton 2006 as having low risk of bias, as the randomisation sequence was computer generated. However, we judged Hossain 2010 as having unclear risk because insufficient information was provided in the abstract. We judged Bilton 2006 as having low risk of bias for allocation concealment following confirmation from trial authors that assignment was concealed via an independent central allocation process. We judged Hossain 2010 as having unclear risk owing to insufficient information provided in the abstract.
Blinding
We judged Bilton 2006 as having low risk of bias for this domain. The principal investigator confirmed that drugs were supplied by a pharmaceutical company in identical opaque vials, and that both drugs had a similar taste. We judged Hossain 2010 as having unclear risk owing to insufficient information provided in the abstract. We judged Bilton 2006 as having low risk of bias following confirmation from the principal investigator that outcome assessors were blinded to group allocation. We judged Hossain 2010 as having unclear risk owing to insufficient information provided in the abstract.
Incomplete outcome data
We judged Bilton 2006 as having high risk of attrition bias because reasons for missing outcome data were not balanced between intervention groups. We judged Hossain 2010 as having unclear risk owing to insufficient information provided in the abstract.
Selective reporting
We classified risk of selective reporting bias as unclear for both of the included studies because information on which to base a clear judgement was insufficient (Bilton 2006; Hossain 2010).
Other potential sources of bias
We judged Bilton 2006 as having low risk of bias for this domain, as no other sources of bias were identified. We judged Hossain 2010 as having unclear risk because information provided in the abstract was insufficient.
Effects of interventions
See: Summary of findings for the main comparison Oral + inhaled dual therapy compared with oral monotherapy for bronchiectasis
Primary outcomes Successful treatment of exacerbation
Bilton 2006 reported no differences between groups in the number of participants cured at day 21 (OR 0.42, 95% CI 0.14 to 1.30; one study; 53 adults; Analysis 1.1) or at day 42 (OR 0.66, 95% CI 0.22 to 2.01; one study; 53 adults; Analysis 1.2). Researchers noted no differences between groups in terms of number of participants with P aeruginosa eradication at day 21 (OR 2.33, 95% CI 0.66 to 8.24; Analysis 1.3). In Hossain 2010, participants receiving dual therapy had an enhanced recovery rate compared with those receiving systemic antibiotics alone at three time points (P = 0.05; P = 0.02; P = 0.02), but which of the four follow-up time points (day 3, 7, 14, or 21) is referred to remains unclear. The study report was available only as an abstract and did not provide any quantitative data other than the P value. According to our GRADE assessment, we judged this outcome as very low quality (Summary of findings for the main comparison).
Length of hospitalisation
Hossain 2010 reported that dual therapy reduced hospital stay among participants in the intervention group; however, the abstract did not include any quantitative data.
Serious adverse events
Bilton 2006 reported no differences between groups in frequency of serious adverse events (OR 0.48, 95% CI 0.08 to 2.87; one study; 53 adults; Analysis 1.4). Four participants receiving monotherapy and two receiving dual therapy required hospitalisation for worsening symptoms such as dyspnoea, cough, and chest pain or tightness. According to our GRADE assessment, we judged this outcome as very low quality (Summary of findings for the main comparison).
Length of exacerbation, time to next exacerbation, frequency of exacerbations
None of the included studies reported any of the above outcomes.
Secondary outcomes
Response rates
Response to treatment -failure or relapse
Treatment responses were not different between groups at day 21 for the classification of treatment failure (OR 2.75, 95% CI 0.79 to 9.62; one study; 53 adults; Analysis 1.5); nor at day 42 for the classifications of treatment relapse (OR 0.57, 95% CI 0.12 to 2.69; one study; 53 adults; Analysis 1.6) and treatment failure (OR 2.75, 95% CI 0.79 to 9.62; one study; 53 adults; Analysis 1.7). Relapse rates were not measured at day 21.
Microbiological response -eradicated, persistent, superinfected
Microbiological response was not different between groups at day 21 for the following classifications: eradicated (OR 2.40, 95% CI 0.67 to 8.65; Analysis 1.8); persistent (OR 0.37, 95% CI 0.11 to 1.26; Analysis 1.9); and superinfected (OR 3.26, 95% CI 0.13 to 83.90; Analysis 1.10). According to our GRADE assessment, we judged this outcome as very low quality (Summary of findings for the main comparison).
Sputum volume and purulence
Bilton 2006 reported no statistically significant differences in mean sputum volume at days 7 and 14 with dual therapy compared with monotherapy.
Measures of lung function
Researchers noted no statistically significant differences in FEV 1 between groups in the included studies. Bilton 2006 reported mean FEV 1 (L) graphically for all data collection points (days 7 and 14), but it was not possible for review authors to accurately retrieve the raw data. Hossain 2010 did not report further details.
Systemic markers of infection
None of the included studies reported this outcome.
Adverse events
Researchers noted no differences between groups in the number of people who experienced an adverse event in Bilton 2006 (OR 0.21, 95% CI 0.02 to 2.03; Analysis 1.11). However, the incidence of wheeze was significantly higher in the dual therapy group compared with the monotherapy group (OR 5.75, 95% CI 1.55 to 21.33; Analysis 1.12). Data show no differences between groups in terms of adverse events arising from the use of study medications, although it is unclear from the paper whether this relates specifically to the antibiotic interventions (OR 1.45, 95% CI 0.49 to 4.31; Analysis 1.13). Hossain 2010 reported that five participants in the dual therapy group developed wheeze and chest tightness following administration of nebulised gentamicin. It remains unclear whether any of the participants in the monotherapy group experienced an adverse event.
Deaths
Neither of the included studies explicitly reported any deaths,
Emergence of resistance to antibiotics
Data show no differences between groups in the development of antibiotic resistance in Bilton 2006. One patient receiving dual tobramycin+ciprofloxacin therapy entered the study with tobramycin-susceptible P aeruginosa strains that became resistant by the end of the study. No participants receiving ciprofloxacin monotherapy developed tobramycin-resistantP aeruginosa strains during the study.
Exercise capacity
Neither Bilton 2006 nor Hossain 2010 reported this outcome.
Quality of life
Neither of the two included studies reported this outcome.
D I S C U S S I O N Summary of main results
Two randomised trials met the inclusion criteria for this systematic review (Bilton 2006; Hossain 2010); both assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy, and both were conducted in adults. Bilton 2006 was a multi-centre trial conducted in UK and USA, and Hossain 2010 was a single-centre study conducted in Bangladesh. Only an abstract was available for Hossain 2010, and outcomes were described narratively or results were reported as the P value alone; therefore we were unable to include these data in the quantitative data synthesis. We found no evidence of treatment effect with oral plus inhaled dual therapy for all outcomes reported in the summary of findings, including successful treatment of exacerbations, serious adverse events, and response rates, although the effect estimate was based on one small study of 53 adults (Bilton 2006). Similarly, we found no evidence of effect on sputum volume, lung function, adverse events, or antibiotic resistance.
Overall completeness and applicability of evidence
Of the pre-defined potential comparison groups, we identified only one group (oral plus inhaled dual therapy vs oral monotherapy) for inclusion in the review. The comparison included only two small studies with a total of 118 participants. Our search did not identify any other comparisons that met our study selection criteria. The two included studies did not report some of our primary outcomes (length, frequency, and time to next exacerbation) and did not report some of our secondary outcomes (systemic markers of infection, exercise capacity, and quality of life). It is particularly important to measure the impact of this chronic condition on health-related quality of life from the patient's perspective. Furthermore, we were unable to obtain quantitative data for pooled analyses or to adequately assess risk of bias for one study, as findings were available only in a conference abstract. We did not identify any studies that evaluated the use of dual antibiotics in children, or that assessed long-term (more than four weeks) use of dual antibiotic therapy; we identified insufficient studies to permit assessment of effects by class of antibiotic. Similarly, we found insufficient studies to conduct sensitivity analyses. Our findings therefore are limited by scant available data, and we were unable to evaluate all outcomes planned in the protocol.
Quality of the evidence
We judged overall quality of the evidence as very low for outcomes included in the GRADE assessment. Only one comparison -oral plus inhaled dual antibiotic versus oral antibiotic alone -was assessed, and included studies did not report several of the outcomes that we planned to include in our GRADE assessment. We judged the quality of evidence as very low for the three outcomes included in the GRADE assessment (treatment of exacerbations, response rate, and serious adverse events). All outcomes were limited by incomplete outcome data. We considered effects as imprecise owing to wide confidence intervals that crossed the line of no effect and inclusion of few events and small sample sizes.
Potential biases in the review process
We used a comprehensive systematic search, conducted by a highly experienced information specialist, to identify potentially eligible studies. We also searched multiple resources including electronic databases, journals, conference proceedings, reference lists of included studies, citations of included studies, and trial registries. Nevertheless, we recognise the possibility of publication bias in this review, which could lead to overestimation or underestimation of effects of the intervention in terms of the different outcomes included in this review. Trials showing no, or negative, effects are less likely to be offered for publication, and, if offered, they are less likely to be accepted, resulting in a biased set of data available for review. We were able to extract quantitative data from only one study and were unable to assess the presence of publication bias through formal testing. Furthermore, some papers may have been misclassified as not eligible for inclusion in the review. However, two review authors independently assessed all studies, and a third review author verified selection, so we are confident that we assessed studies excluded from the analyses on the basis of consistent and appropriate criteria. We double-checked all data to avoid extraction and transcription errors. We contacted the investigators of both included studies to request further information on trial methods and outcome data. The author of one trial, published as a full-text paper, provided clarification on randomisation procedures. We did not receive a response from the authors of the study that was published only as an abstract. We also contacted the author of one excluded study published in a non-English language but did not receive a response. We obtained translations of two non-English language studies that we excluded following inspection of the translated text. We were unable to conduct planned subgroup or sensitivity analyses owing to the small number of included studies.
Agreements and disagreements with other studies or reviews
There are no previous versions of this review. We included in this review two small trials that assessed the effectiveness of oral plus inhaled dual therapy versus oral monotherapy alone, with a total of 118 adult participants and no children. We highlighted the paucity of evidence in this area in relation to all important outcomes and, in accordance with this lack of evidence, identified no published reviews of the relevant benefits and risks of combined antibiotics compared with monotherapy in bronchiectasis. A review of single versus combination intravenous antibiotics for eradicating Pseudomonas aeruginosa in people with cystic fibrosis found no significant benefit associated with a beta-lactam or aminoglycoside monotherapy compared with a beta-lactam-aminoglycoside combination upon examination of poor quality evidence (Elphick 2005). However, recent bronchiectasis guidelines emphasise differences in treatment responses between bronchiectasis and cystic fibrosis, and although the guidelines provide no specific recommendations for dual therapy, they do offer recommendations for use of antibiotics in people with this condition (Polverino 2017). This review cannot inform robust recommendations for practice owing to insufficient high-quality evidence, and review authors found no evidence related to the role of dual antibiotics in the treatment of children.
A U T H O R S ' C O N C L U S I O N S Implications for practice
This systematic review identified minimal published evidence to guide clinical practice on the routine use of dual antibiotics for treatment of patients with bronchiectasis.
Only two published trials with 118 adult participants met our inclusion criteria; these studies evaluated the addition of nebulised aminoglycosides to systemic antibiotics. Bilton and colleagues investigated the addition of nebulised tobramycin to oral ciprofloxacin for treatment of 53 adult patients with acute Pseudomonas aeruginosa infection in bronchiectasis. Researchers found no evidence of treatment benefit with oral plus inhaled dual therapy in terms of successful treatment of exacerbations, serious adverse events, sputum volume, lung function, and antibiotic resistance. Hossain reported the results of a single-centre placebo-controlled comparison of systemic antimicrobials versus the addition of nebulised gentamicin, but we were unable to include this study in the quantitative synthesis. Both studies reported a higher incidence of wheeze with dual therapy. Overall, we have very low confidence in the outcomes presented.
Review authors have identified the need for better quality evidence on the benefits and risks of dual antibiotics to guide clinical practice in the treatment of patients with bronchiectasis.
Implications for research
Our review highlights the need for additional long-term randomised placebo-controlled trials to determine the effectiveness of dual antibiotics versus single antibiotics for treatment of adults and children with bronchiectasis. The two included studies compared oral plus inhaled dual therapy versus oral therapy alone, but no trials have compared other combinations of modes of administration (e.g. intravenous and inhaled; different antibiotics delivered via a common mode of administration, such as two inhaled antibiotics). Some evidence from observational studies of dual antibiotic regimens suggests that including nebulised antibiotics is more effective than providing intravenous regimens alone for eradicating Pseudomonas aeruginosa. (Orriols 1999), This and other comparisons require formal testing in randomised controlled trials to establish the relative benefits of different types of dual therapy. The overall quality of evidence derived from the two included studies is very poor, and we found no data on our primary outcomes of duration, frequency, or time to next exacerbation, nor on our secondary outcomes of microbiological infection measures, exercise capacity, and quality of life. Furthermore neither of the included trials enrolled children or investigated long-term (more than four weeks) use of dual antibiotic therapy. Future high-quality studies should consider both short-and long-term antibiotic management for adults and children including our prespecified review outcomes, especially health-related quality of life, and should report data on adults and children separately. We also consider it important to assess the relative risks and benefits of continuous versus cyclical antibiotic administration, but this question will be addressed in a separate review.
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C H A R A C T E R I S T I C S O F S T U D I E S Characteristics of included studies [ordered by study ID]
Bilton 2006
Methods Aims: to test the effect of adding tobramycin inhaled solution to oral ciprofloxacin for the treatment of acute exacerbations of non-cystic fibrosis bronchiectasis in patients with P aeruginosa infection Design: a double-blind, randomised, active comparator, parallel-design study Total study duration: 42 days from randomisation, not including the 28-day prescreening run-in period. Elapsed time between pre-screening and randomisation differed for each participant as participants were randomised during an exacerbation Number of study centres and locations: multiple (17 centres): 5 in the United Kingdom, 12 in the United States Study setting: home (participants received the first dose of study drug on day 1 in the presence of study personnel but took subsequent doses at home) Methods of recruitment: unclear Study start and end dates: not reported Withdrawals: 10 participants withdrew from the study (5 from inhaled tobramycin + oral ciprofloxacin group, 5 from oral ciprofloxacin group). Seven withdrawals (2 from inhaled tobramycin + oral ciprofloxacin group and 5 from oral ciprofloxacin group) were due to adverse events. Among these, 3 participants (1 from inhaled tobramycin + oral ciprofloxacin group, and 2 from oral ciprofloxacin group) withdrew owing to possibly drug-related adverse events, and 4 in the oral ciprofloxacin group withdrew on day 21 or later owing to non-drug-related adverse events. Three participants in the inhaled tobramycin + oral ciprofloxacin group withdrew from the study owing to "unsatisfactory therapy responses" after receiving 8, 8, and 15 days of dosing, respectively. One participant from the inhaled tobramycin + oral ciprofloxacin group who withdrew at day 8 owing to "unsatisfactory therapeutic responses" also had an adverse event Analysis by intent to treat: yes. It was reported that "safety and efficacy analysis was performed on the study population, which included all randomised participants who had received at least one dose of study medication."
Participants 53 adults were randomised Inclusion criteria: history of chronic P aeruginosa lung infection, confirmed by a sputum culture that was positive for P aeruginosa both within 12 months before screening and at the time of screening. In addition, P aeruginosa had to show ciprofloxacin sensitivity (mic < 4) at the time of study enrolment. Participants who did not experience an acute exacerbation within 2 months of the screening visit were rescreened for study eligibility Exclusion criteria: cystic fibrosis, allergic bronchopulmonary aspergillosis, active tuberculosis, glucose-6-phosphate dehydrogenase deficiency, significant renal disease, change in steroid therapy within 2 weeks of exacerbation 
